NSE - Delayed Quote INR

Aarti Drugs Limited (AARTIDRUGS.NS)

Compare
458.40 +2.95 (+0.65%)
At close: 3:29 PM GMT+5:30
Loading Chart for AARTIDRUGS.NS
DELL
  • Previous Close 455.45
  • Open 459.00
  • Bid --
  • Ask --
  • Day's Range 456.80 - 469.15
  • 52 Week Range 431.05 - 635.00
  • Volume 92,084
  • Avg. Volume 164,542
  • Market Cap (intraday) 41.935B
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) 27.65
  • EPS (TTM) 16.58
  • Earnings Date Jan 22, 2025 - Jan 27, 2025
  • Forward Dividend & Yield 1.00 (0.22%)
  • Ex-Dividend Date Feb 6, 2024
  • 1y Target Est 555.00

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

www.aartidrugs.co.in

1,064

Full Time Employees

March 31

Fiscal Year Ends

Recent News: AARTIDRUGS.NS

View More

Performance Overview: AARTIDRUGS.NS

Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AARTIDRUGS.NS
6.12%
S&P BSE SENSEX
9.42%

1-Year Return

AARTIDRUGS.NS
4.42%
S&P BSE SENSEX
19.82%

3-Year Return

AARTIDRUGS.NS
10.61%
S&P BSE SENSEX
38.41%

5-Year Return

AARTIDRUGS.NS
254.36%
S&P BSE SENSEX
92.69%

Compare To: AARTIDRUGS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AARTIDRUGS.NS

View More

Valuation Measures

Annual
As of 11/27/2024
  • Market Cap

    41.66B

  • Enterprise Value

    47.27B

  • Trailing P/E

    27.49

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    3.25

  • Enterprise Value/Revenue

    2.00

  • Enterprise Value/EBITDA

    16.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.40%

  • Return on Assets (ttm)

    6.17%

  • Return on Equity (ttm)

    12.24%

  • Revenue (ttm)

    23.8B

  • Net Income Avi to Common (ttm)

    1.52B

  • Diluted EPS (ttm)

    16.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    295.6M

  • Total Debt/Equity (mrq)

    46.18%

  • Levered Free Cash Flow (ttm)

    837.4M

Research Analysis: AARTIDRUGS.NS

View More

Company Insights: AARTIDRUGS.NS

Research Reports: AARTIDRUGS.NS

View More

People Also Watch